ArticleJournal of clinical and experimental hepatology
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Splenic Steatopathy: A Clinical and Experimental Framework for Lipid-Associated Splenic Pathology.Clinical and experimental gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Portal hypertension is a major complication in metabolic dysfunction-associated steatotic liver disease (MASLD). In the PEMA-FL (PEMAfibrate randomised placebo-controlled study in patients with non-alcoholic fatty liver disease) phase 2 trial, this Methods: This 72-week, multicenter, randomized, double-blind, placebo-controlled phase 2 study enrolled 118 patients with high-risk MASLD, randomized 1:1 to pemafibrate 0.4 mg/day or placebo. Platelet count, liver stiffness, and spleen volume were assessed at baseline and during follow-up. Percent changes and parameter associations were evaluated in an exploratory Results: Pemafibrate administration was associated with an early and sustained increase in platelet count during follow-up. Liver stiffness showed a gradual decline from week 24 in the pemafibrate group and stabilized after week 48. At week 72, spleen volume decreased in the pemafibrate group, whereas no reduction was observed in the placebo group. In patients with metabolic dysfunction-associated steatohepatitis (MASH), changes in platelet count, liver stiffness, and spleen volume were more pronounced than in those without MASH. At week 72, changes in spleen volume correlated positively with changes in liver stiffness and negatively with platelet count, with a stronger association observed for liver stiffness. In contrast, platelet count changes did not correlate with liver stiffness. Conclusion: In this exploratory
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.